157 related articles for article (PubMed ID: 31809044)
1. Synthesis and PTP Inhibitory Activity of Illudalic Acid and Its Methyl Ether, with Insights into Selectivity for LAR PTP over Other Tyrosine Phosphatases under Physiologically Relevant Conditions.
McCullough BS; Batsomboon P; Hutchinson KB; Dudley GB; Barrios AM
J Nat Prod; 2019 Dec; 82(12):3386-3393. PubMed ID: 31809044
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and LAR inhibition of 7-alkoxy analogues of illudalic acid.
Ling Q; Zhou YY; Cai ZL; Zhang YH; Xiong B; Ma LP; Wang X; Li X; Li J; Shen JK
Yao Xue Xue Bao; 2010 Nov; 45(11):1385-97. PubMed ID: 21355526
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of covalent inhibition of LAR phosphatase by illudalic acid.
Hansen DT; Rueb NJ; Levinzon ND; Cheatham TE; Gaston R; Tanvir Ahmed K; Osburn-Staker S; Cox JE; Dudley GB; Barrios AM
Bioorg Med Chem Lett; 2024 May; 104():129740. PubMed ID: 38599294
[TBL] [Abstract][Full Text] [Related]
4. Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action.
Ling Q; Huang Y; Zhou Y; Cai Z; Xiong B; Zhang Y; Ma L; Wang X; Li X; Li J; Shen J
Bioorg Med Chem; 2008 Aug; 16(15):7399-409. PubMed ID: 18579388
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of illudalic acid and analogous phosphatase inhibitors.
Fulo HF; Rueb NJ; Gaston R; Batsomboon P; Ahmed KT; Barrios AM; Dudley GB
Org Biomol Chem; 2021 Dec; 19(48):10596-10600. PubMed ID: 34847212
[TBL] [Abstract][Full Text] [Related]
6. Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.
Zhang ZY
Acc Chem Res; 2017 Jan; 50(1):122-129. PubMed ID: 27977138
[TBL] [Abstract][Full Text] [Related]
7. The second catalytic domain of protein tyrosine phosphatase delta (PTP delta) binds to and inhibits the first catalytic domain of PTP sigma.
Wallace MJ; Fladd C; Batt J; Rotin D
Mol Cell Biol; 1998 May; 18(5):2608-16. PubMed ID: 9566880
[TBL] [Abstract][Full Text] [Related]
8. Rapid and irreversible inactivation of protein tyrosine phosphatases PTP1B, CD45, and LAR by peroxynitrite.
Takakura K; Beckman JS; MacMillan-Crow LA; Crow JP
Arch Biochem Biophys; 1999 Sep; 369(2):197-207. PubMed ID: 10486138
[TBL] [Abstract][Full Text] [Related]
9. The leukocyte common antigen-related protein LAR: candidate PTP for inhibitory targeting.
Mooney RA; LeVea CM
Curr Top Med Chem; 2003; 3(7):809-19. PubMed ID: 12678846
[TBL] [Abstract][Full Text] [Related]
10. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.
McCain DF; Wu L; Nickel P; Kassack MU; Kreimeyer A; Gagliardi A; Collins DC; Zhang ZY
J Biol Chem; 2004 Apr; 279(15):14713-25. PubMed ID: 14734566
[TBL] [Abstract][Full Text] [Related]
11. Protein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function.
Xie Y; Massa SM; Ensslen-Craig SE; Major DL; Yang T; Tisi MA; Derevyanny VD; Runge WO; Mehta BP; Moore LA; Brady-Kalnay SM; Longo FM
J Biol Chem; 2006 Jun; 281(24):16482-92. PubMed ID: 16613844
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of a potent and selective protein tyrosine phosphatase inhibitor, 2.
Hamaguchi T; Takahashi A; Kagamizono T; Manaka A; Sato M; Osada H
Bioorg Med Chem Lett; 2000 Dec; 10(23):2657-60. PubMed ID: 11128645
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.
Henderson IM; Zeng F; Bhuiyan NH; Luo D; Martinez M; Smoake J; Bi F; Perera C; Johnson D; Prisinzano TE; Wang W; Uhl GR
Biochem Pharmacol; 2022 Jan; 195():114868. PubMed ID: 34863978
[TBL] [Abstract][Full Text] [Related]
14. Development of fluorescence-based selective assays for serine/threonine and tyrosine phosphatases.
Pastula C; Johnson I; Beechem JM; Patton WF
Comb Chem High Throughput Screen; 2003 Jun; 6(4):341-6. PubMed ID: 12769677
[TBL] [Abstract][Full Text] [Related]
15. LAR protein tyrosine phosphatase receptor associates with TrkB and modulates neurotrophic signaling pathways.
Yang T; Massa SM; Longo FM
J Neurobiol; 2006 Nov; 66(13):1420-36. PubMed ID: 17013927
[TBL] [Abstract][Full Text] [Related]
16. The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1.
Pulido R; Serra-Pagès C; Tang M; Streuli M
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11686-90. PubMed ID: 8524829
[TBL] [Abstract][Full Text] [Related]
17. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach.
Wu JW; Zhang H; Li WY; Tang X; Li HL; Lu XH; Zheng ZH; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Nov; 38(18):5338-5348. PubMed ID: 31787068
[TBL] [Abstract][Full Text] [Related]
18. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation.
Denu JM; Tanner KG
Biochemistry; 1998 Apr; 37(16):5633-42. PubMed ID: 9548949
[TBL] [Abstract][Full Text] [Related]
19. The myeloperoxidase-derived oxidant hypothiocyanous acid inhibits protein tyrosine phosphatases via oxidation of key cysteine residues.
Cook NL; Moeke CH; Fantoni LI; Pattison DI; Davies MJ
Free Radic Biol Med; 2016 Jan; 90():195-205. PubMed ID: 26616646
[TBL] [Abstract][Full Text] [Related]
20. Targeting Tyrosine Phosphatases: Time to End the Stigma.
Stanford SM; Bottini N
Trends Pharmacol Sci; 2017 Jun; 38(6):524-540. PubMed ID: 28412041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
